Literature summary for 3.4.21.98 extracted from

Raboisson, P.; Lin, T.I.; Kock, H.; Vendeville, S.; Vreken, W.V.; McGowan, D.; Tahri, A.; Hu, L.; Lenz, O.; Delouvroy, F.; Surleraux, D.; Wigerinck, P.; Nilsson, M.; Rosenquist, S.; Samuelsson, B.; Simmen, K.
Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors (2008), Bioorg. Med. Chem. Lett., 18, 5095-5100.

Search for more literature for 3.4.21.98

Inhibitors

Inhibitors	Comment	Organism	Structure
N-{17-[8-chloro-2-(4-isopropylthiazol-2-yl)-7-methoxy-quinolin-4-yloxy]-2,14-dioxo-3,15-diazatricyclo [13.3.0.0]octadec-7-ene-4-carbonyl}-(1-methylcyclo propyl)-(1-methylcyclopropyl)sulfonamide	EC50 = 3.76 nM, non-cytotoxic (CC50 above 0.020 nM), and metabolically stable HCV inhibitor. Compound exhibits advantageous drug metabolism and pharmacokinetic properties in rat and dog, with a high liver exposure after oral administration, but limited heart exposure observed in rat	Hepacivirus C

Organism

Organism	UniProt	Comment	Textmining
Hepacivirus C	-	-	-

Synonyms

Synonyms	Comment	Organism
HCV NS3/4A	-	Hepacivirus C

Ki Value [mM]

Ki Value [mM]	Ki Value maximum [mM]	Inhibitor	Comment	Organism	Structure
0.0000002	-	N-[17-[8-chloro-2-(4-isopropylthiazol-2-yl)-7-methoxy-quinolin-4-yloxy]-2,14-dioxo-3,15-diazatricyclo [13.3.0.0]octadec-7-ene-4-carbonyl]-(1-methylcyclo propyl)-(1-methylcyclopropyl)sulfonamide	-	Hepacivirus C

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)